Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Oncotelic Therapeutics, Inc. (OTLC) had Consolidated Net Income/Loss of $-2.24M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-2.19M |
|
-- |
|
-- |
|
$1.85M |
|
$-1.85M |
|
$-0.39M |
|
$-2.24M |
|
$-2.24M |
|
$-2.24M |
|
$-2.24M |
|
|
Consolidated Net Income/Loss |
$-2.24M |
$-2.24M |
|
$-1.85M |
|
$-1.71M |
|
443.80M |
|
443.80M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$2.06M |
|
-- |
|
$391.89M |
|
$393.95M |
|
$18.40M |
|
$1.79M |
|
$113.34M |
|
$131.74M |
|
$262.21M |
|
$259.42M |
|
$262.21M |
|
444.20M |
|
| Cash Flow Statement Financials | |
$-0.34M |
|
-- |
|
$0.32M |
|
$0.11M |
|
$0.08M |
|
$-0.03M |
|
$1.77M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.11 |
|
-- |
|
-- |
|
0.01 |
|
0.05 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.34M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-0.85% |
|
-0.86% |
|
-0.57% |
|
-0.85% |
|
$0.59 |
|
$-0.00 |
|
$-0.00 |
|